Chinese PLA General Hosptial
Beijing, Beijing Municipality, 100853, China
NCT Number: NCT07112755
This study aims to develop a clinical prediction model for osteopenia in patients with psoriasis. By retrospectively analyzing demographic, laboratory, and lifestyle variables, the investigators will identify risk factors associated with decreased bone mineral density (BMD) in this population. The study will facilitate the identification of high-risk individuals and provide evidence for early screening and intervention strategies.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Beijing, Beijing Municipality, 100853, China
Psoriasis is a chronic inflammatory skin disease associated with various systemic comorbidities, including an increased risk of bone loss. Recent studies suggest that patients with psoriasis have a significantly higher incidence of osteopenia and osteoporosis than the general population, potentially due to systemic inflammation and shared risk factors. All enrolled patients will undergo dual-energy X-ray absorptiometry (DEXA) scans to assess bone mineral density (BMD). Based on the results, patients will be categorized into normal BMD and osteopenia groups. Demographic data (age, sex, height, weight, BMI), clinical variables (disease duration, CRP, ESR, blood glucose, blood lipids, blood pressure), and lifestyle factors (smoking, alcohol use) will be collected and analyzed. Univariate and multivariate logistic regression analyses will be performed to identify independent risk factors. A prediction model will be constructed and evaluated using ROC curve analysis to assess sensitivity, specificity, and accuracy. The objective of this study is to develop a validated tool to assist clinicians in identifying patients with psoriasis at high risk for osteopenia, thereby enabling early screening and preventive management to reduce future fracture risk.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At the time of DEXA assessment during enrollment
Bone mineral density (BMD) will be assessed using dual-energy X-ray absorptiometry (DEXA) at the lumbar spine and/or femoral neck. Osteopenia is defined as a T-score between -1.0 and -2.5 according to WHO criteria. Patients will be categorized accordingly.
Chongli Yu
Other
Development of a Risk Prediction Model for Osteopenia in Patients With Psoriasis: A Cross-Sectional Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07140666
Bone Diseases, Bone Diseases, Metabolic
Beijing, Beijing Municipality, China
View Trial DetailsNCT01778569
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT05295979
Psoriasis, Skin Diseases
Hong Kong
View Trial DetailsNCT04728165
Psoriasis, Skin Diseases
Bethesda, Maryland, United States
View Trial Details